1. Clinical Overview
A fixed-dose combination topical preparation containing a potent corticosteroid (Betamethasone), an aminoglycoside antibiotic (Gentamicin), and an imidazole antifungal (Miconazole). It is designed for the treatment of inflammatory dermatoses complicated by or at high risk of bacterial and fungal infections, commonly seen in the hot and humid Indian climate. It provides anti-inflammatory, antibacterial, and antifungal actions in a single formulation.
| Onset | Duration | Bioavailability |
|---|---|---|
| Anti-inflammatory effects begin within 1-3 hours; symptomatic relief of pruritus and erythema is often noted within 12-24 hours. Antimicrobial effects begin upon contact. | Topical corticosteroid effect can last 12-48 hours after application. The antimicrobial effect is dependent on continued presence at the site. | Topical bioavailability is low but variable (1-5% for betamethasone, minimal systemic absorption for gentamicin and miconazole from intact skin). Absorption increases significantly on inflamed, broken, or occluded skin and in pediatric patients. |
2. Mechanism of Action
The combination exerts a triple action: 1) BETAMETHASONE: A potent glucocorticoid that binds to intracellular glucocorticoid receptors, leading to the synthesis of anti-inflammatory proteins (lipocortin) and inhibition of pro-inflammatory mediators (prostaglandins, leukotrienes, cytokines). It suppresses inflammation, vasoconstriction, and pruritus. 2) GENTAMICIN: A bactericidal aminoglycoside that binds irreversibly to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing cell death. Effective against common skin pathogens like Staphylococcus aureus and Pseudomonas aeruginosa. 3) MICONAZOLE: An imidazole antifungal that inhibits the synthesis of ergosterol, a vital component of the fungal cell membrane, by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase. This leads to increased membrane permeability and cell death. It also has some gram-positive antibacterial activity.
3. Indications & Uses
- Inflammatory dermatoses with secondary or suspected bacterial and fungal infections (e.g., infected eczema, infected contact dermatitis)
- Intertrigo (inflammatory rash in skin folds) with candidal and/or bacterial superinfection
- Tinea corporis/cruris (ringworm) with severe inflammation and secondary infection
- Seborrheic dermatitis with secondary infection in severe cases
4. Dosage & Administration
Adult Dosage: Apply a thin film to the affected area 2-3 times daily, or as directed by the physician. Duration should be limited to a maximum of 2 weeks.
Administration: 1. Wash and dry the affected area gently. 2. Take a small amount of cream/ointment on a clean fingertip. 3. Apply a thin layer and rub in gently until absorbed. 4. Wash hands before and after application, unless hands are the treatment site. 5. Do not cover with occlusive dressings unless specifically advised by a doctor. 6. Avoid contact with eyes, nose, mouth, and other mucous membranes.
5. Side Effects
Common side effects may include:
- Local burning or stinging sensation (especially on broken skin)
- Itching
- Dryness of skin
- Erythema
- Contact dermatitis (irritant or allergic)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other Topical Corticosteroids | Additive risk of local and systemic side effects (atrophy, HPA suppression). | Major |
| Systemic Aminoglycosides (e.g., Amikacin, Streptomycin) | Increased risk of ototoxicity and nephrotoxicity if gentamicin is absorbed systemically. | Major |
| Warfarin and other Coumarin Anticoagulants | Miconazole (systemic) can potentiate anticoagulant effect. Significance with topical use is low but monitor if applied to large areas. | Moderate |
| Oral Hypoglycemic Agents (Sulfonylureas) | Miconazole may potentiate hypoglycemic effect. Clinical significance with topical use is uncertain. | Moderate |
| Cyclosporine, Tacrolimus (Topical Calcineurin Inhibitors) | Concurrent use not recommended; increased risk of infection and potential additive immunosuppression. | Major |
7. Patient Counselling
- DO use exactly as prescribed by your doctor.
- DO apply a thin layer only to the affected area.
- DO wash your hands before and after application.
- DO report any lack of improvement or worsening after 3-4 days.
- DON'T use it for longer than the prescribed duration (usually 1-2 weeks).
- DON'T apply to the face, groin, or armpits unless specifically directed.
- DON'T cover the area with tight bandages or plastic wraps unless advised.
- DON'T use it for conditions it was not prescribed for.
- DON'T allow the medication to come into contact with eyes.
8. Toxicology & Storage
Overdose: Topical overdose manifests as severe local side effects: pronounced skin atrophy, striae, telangiectasia, HPA axis suppression (symptoms: weight gain, moon face, hypertension, hyperglycemia, muscle weakness). Systemic gentamicin toxicity (ototoxicity: tinnitus, hearing loss; nephrotoxicity) is possible with massive application over large body surface areas, especially with impaired renal function.
Storage: Store at room temperature (15-25°C), protected from light and moisture. Do not freeze. Keep the tube tightly closed. Keep out of reach and sight of children. Do not use after the expiry date printed on the pack.